View Future GrowthThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsVapotherm 과거 순이익 실적과거 기준 점검 0/6Vapotherm 의 수입은 연평균 -10.3%의 비율로 감소해 온 반면, Medical Equipment 산업은 연평균 15.3%의 비율로 증가했습니다. 매출은 연평균 0.4%의 비율로 감소해 왔습니다.핵심 정보-10.27%순이익 성장률9.41%주당순이익(EPS) 성장률Medical Equipment 산업 성장률8.90%매출 성장률-0.36%자기자본이익률n/a순이익률-76.74%최근 순이익 업데이트30 Jun 2024최근 과거 실적 업데이트공고 • Nov 02Vapotherm, Inc. to Report Q3, 2023 Results on Nov 08, 2023Vapotherm, Inc. announced that they will report Q3, 2023 results After-Market on Nov 08, 2023공고 • Jul 26Vapotherm, Inc. to Report Q2, 2023 Results on Aug 08, 2023Vapotherm, Inc. announced that they will report Q2, 2023 results After-Market on Aug 08, 2023공고 • May 05+ 1 more updateVapotherm, Inc. Reports Impairment of Long-Lived and Intangible Assets for the First Quarter Ended March 31, 2023Vapotherm, Inc. reported impairment of long-lived and intangible assets for the first quarter ended March 31, 2023. For the quarter, the company reported impairment of long-lived and intangible assets of $432,000.공고 • Feb 09+ 2 more updatesVapotherm, Inc. to Report Q4, 2022 Results on Feb 23, 2023Vapotherm, Inc. announced that they will report Q4, 2022 results After-Market on Feb 23, 2023Reported Earnings • Feb 27Full year 2021 earnings: EPS and revenues exceed analyst expectationsFull year 2021 results: US$2.31 loss per share (down from US$2.16 loss in FY 2020). Revenue: US$113.3m (down 9.9% from FY 2020). Net loss: US$59.8m (loss widened 16% from FY 2020). Revenue exceeded analyst estimates by 3.2%. Earnings per share (EPS) also surpassed analyst estimates by 3.6%. Over the next year, revenue is expected to shrink by 9.6% compared to a 11% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 06Third quarter 2021 earnings released: US$0.52 loss per share (vs US$0.49 loss in 3Q 2020)The company reported a solid third quarter result with improved revenues and control over costs, although losses increased. Third quarter 2021 results: Revenue: US$38.1m (up 25% from 3Q 2020). Net loss: US$13.6m (loss widened 9.0% from 3Q 2020).모든 업데이트 보기Recent updates공고 • Sep 20Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC completed the acquisition of Vapotherm, Inc. (OTCPK:VAPO) from a group of shareholders.Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC executed the non binding term sheet to acquire Vapotherm, Inc. (OTCPK:VAPO) from a group of shareholders on April 29, 2024. Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC entered into definitive merger agreement to acquire Vapotherm, Inc. from a group of shareholders for $15.2 million on June 17, 2024. Vapotherm’s stockholders will receive $2.18 in cash for each outstanding share of Company common stock. Perceptive will invest $50.0 million of new preferred equity capital into the business, a portion of which will be used to fund the merger consideration and make certain closing-related payments. Upon termination of the Merger Agreement under certain specified circumstances, Vapotherm will be required to pay Perceptive a termination fee of $1.0 million. Acting upon the recommendation of the Special Committee, the Board approved the merger agreement and the transaction and has recommended that the Company’s stockholders approve the adoption of the merger agreement and approve the transaction on the terms set forth in the merger agreement. The board of directors of Perceptive also approved the agreement. The transaction is expected to close in the second half of 2024. Eric Blanchard and Amelia Runyan Davis of Cooley LLP is acting as legal counsel to Perceptive and Latham & Watkins LLP is acting as legal counsel to SLR. Scalar, LLC is acting as financial advisor and fairness opinion provider to the Special Committee and Paul Kinsella and Sarah Young of Ropes & Gray LLP is acting as legal counsel to the Vapotherm. Haim Zaltzman and Daniel Mun of Latham & Watkins LLP acted as legal counsel for SLR Investment Corp., public fund managed by SLR Capital Partners, LLC. Vapotherm has retained Morrow Sodali LLC, a proxy solicitor, to solicit proxies in connection with the Special Meeting at a cost of approximately $20,000 plus expenses. Scalar received a fee of $140,000 from Vapotherm for providing its services and rendering its opinion. Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC completed the acquisition of Vapotherm, Inc. (OTCPK:VAPO) from a group of shareholders on September 20, 2024. Effective as of the closing of the merger, trading of Vapotherm’s common stock has been suspended on OTCQX, and Vapotherm has requested that its common stock be delisted from OTCQX. Vapotherm shareholders approved the transaction on September 19, 2024.공고 • Jun 18Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC entered into definitive merger agreement to acquire Vapotherm, Inc. (OTCPK:VAPO) for $15.1 million.Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC entered into definitive merger agreement to acquire Vapotherm, Inc. (OTCPK:VAPO) for $15.1 million on June 17, 2024. Vapotherm’s stockholders will receive $2.18 in cash for each outstanding share of Company common stock. Perceptive will invest $50.0 million of new preferred equity capital into the business, a portion of which will be used to fund the merger consideration and make certain closing-related payments. Acting upon the recommendation of the Special Committee, the Board approved the merger agreement and the transaction and has recommended that the Company’s stockholders approve the adoption of the merger agreement and approve the transaction on the terms set forth in the merger agreement. The transaction is expected to close in the second half of 2024. Cooley LLP is acting as legal counsel to Perceptive and Latham & Watkins LLP is acting as legal counsel to SLR. Scalar, LLC is acting as financial advisor to the Special Committee and Ropes & Gray LLP is acting as legal counsel to the Vapotherm.공고 • Mar 15Vapotherm, Inc. to Unveil Access365 Home Ventilation Solution at MEDTRADEVapotherm, Inc. announced the debut of its Access365™ Home Ventilation Solution at the upcoming MEDTRADE conference. The highly anticipated Access365 home ventilator will be unveiled at MEDTRADE Dallas on March 27th. The device is designed to reduce hospital readmissions, improve patient quality of life, and reduce HME costs for late-stage hypercapnic COPD patients. In addition to VAPS and volume control/assist ventilation modes and Vapotherm's proven high velocity therapy, the ventilator incorporates a built-in medical grade humidifier and integrated Bluetooth pulse oximetry and spirometry. The Access365 Home Ventilation Solution also includes cloud connectivity to enable remote data retrieval and system upgrades and a patient engagement platform which breaks the cycle of symptom exacerbation and readmission through early identification of worsening symptoms allowing more rapid clinical intervention. This proprietary algorithm resulted in up to a 41% reduction in late-stage COPD hospital readmissions. Vapotherm anticipates receiving FDA clearance for Access365 in early 2025.공고 • Dec 15The New York Stock Exchange to Commence Delisting Proceedings against VapothermThe New York Stock Exchange (‘NYSE’, the ‘Exchange’) announced that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Vapotherm, Inc. (the ‘Company’) from the NYSE. Trading in the Company’s common stock will be suspended immediately. NYSE Regulation reached its decision to delist the Company’s common stock pursuant to Section 802.01B of the NYSE’s Listed Company Manual because the Company had fallen below the NYSE’s continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15,000,000. The Company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange. The NYSE will apply to the Securities and Exchange Commission to delist the common stock upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision.공고 • Nov 11Vapotherm, Inc. Revises Revenue Guidance for the Full Year 2023Vapotherm, Inc. revised revenue guidance for the full Year 2023. The Company now expects full year revenue to be between $69 million and $71 million, a decrease from the Company’s previous fiscal outlook of $70 million to $73 million.공고 • Nov 02Vapotherm, Inc. to Report Q3, 2023 Results on Nov 08, 2023Vapotherm, Inc. announced that they will report Q3, 2023 results After-Market on Nov 08, 2023공고 • Sep 26Vapotherm Announces Presentation of an Investigator-Initiated Clinical Trial, 'High Flow Humidified Oxygen as an Early Intervention in Children with Acute Severe Asthma - a Feasibility Randomized Controlled Trial' at the European Respiratory Society International Congress 2023Vapotherm, Inc. announced the presentation of an Investigator-initiated clinical trial, “High flow humidified oxygen as an early intervention in children with acute severe asthma - a feasibility randomized controlled trial” at the European Respiratory Society International Congress 2023. The study was conducted through the Brighton and Sussex Clinical Trial Unit at University Hospitals, Sussex, England under the direction of Drs. Hector Rojas-Anaya and Paul Seddon. Children who presented to the Emergency Department with acute, severe, asthma exacerbations that did not respond to initial pharmacologic treatment were randomized to either HVNI or standard nasal oxygen therapy. 86% (19/22) of children treated with standard oxygen required escalation of therapy, while only 61% (17/28) of children treated with HVNI needed further escalation. In addition, children treated with HVNI met hospital discharge criteria in a median time of 29 hours, compared to a median time of 37 hours for those treated with standard oxygen. Studies of acute asthma and other emergent conditions are limited, in part, by the challenge of obtaining informed consent. This study demonstrated the feasibility of pediatric emergency studies utilizing coordinated care and delayed informed consent.공고 • Aug 09Vapotherm, Inc. Revises Earnings Guidance for Fiscal 2023Vapotherm, Inc. revised earnings guidance For fiscal 2023. For the period, the Company now expects full year revenue to be between $70 million and $73 million, a decrease from its previous expectation of $77 million to $79 million. The Company now expects full year gross margins of 43% to 45%, a decrease from its previous expectation of 48% to 50%.공고 • Jul 26Vapotherm, Inc. to Report Q2, 2023 Results on Aug 08, 2023Vapotherm, Inc. announced that they will report Q2, 2023 results After-Market on Aug 08, 2023공고 • May 05+ 1 more updateVapotherm, Inc. Reports Impairment of Long-Lived and Intangible Assets for the First Quarter Ended March 31, 2023Vapotherm, Inc. reported impairment of long-lived and intangible assets for the first quarter ended March 31, 2023. For the quarter, the company reported impairment of long-lived and intangible assets of $432,000.공고 • Feb 10Vapotherm Receives Price Cure Notification Letter from the NYSE Indicates its Stock Price Above the NYSE's Minimum RequirementVapotherm, Inc. announced that with respect to the previously reported two delisting notices from the New York Stock Exchange (NYSE) in 2022, the company reported that it recently received a price cure notification letter from the NYSE indicating the company’s stock price was above the NYSE’s minimum requirement of one dollar per share based on a 30-trading day average. Accordingly, the company is no longer considered below the one dollar continued listing criterion. The company recently received a plan acceptance letter from the NYSE indicating it had accepted the company’s previously submitted business plan to cure its non-compliance with its market capitalization requirement. As set forth in the acceptance letter, the NYSE will continue listing the Company and will perform quarterly reviews for an 18-month period that started September 27, 2022 (the date the delisting notice was received by the Company) for compliance with the goals and initiatives outlined in the Company’s business plan, which are consistent with the key initiatives the Company has publicly disclosed. The Company will need to achieve the minimum continued listing standards of either average global market capitalization over a consecutive 30 trading-day period of $50 million or total stockholders’ equity of $50 million at the completion of the 18-month period.공고 • Feb 09+ 2 more updatesVapotherm, Inc. to Report Q4, 2022 Results on Feb 23, 2023Vapotherm, Inc. announced that they will report Q4, 2022 results After-Market on Feb 23, 2023Seeking Alpha • Feb 08Vapotherm announces $23M private placementGlobal medical technology company, Vapotherm (NYSE:VAPO) has entered into a securities purchase agreement with investors through a private placement financing for gross proceeds of ~$23M. Pursuant to the agreement, the company agreed to issue 17.5M shares and pre-funded warrants to purchase up to 4.4M shares. The pre-funded warrants will have a term of 30 years and an exercise price of $0.001 per share. Closing expected to occur on February 10, 2023. Net proceeds from the offering primarily for sales and marketing, working capital, and other general corporate purposes. Stock trades 8% higher.Seeking Alpha • Nov 02Vapotherm GAAP EPS of -$0.98 misses by $0.20, revenue of $13.5M misses by $3.02MVapotherm press release (NYSE:VAPO): Q3 GAAP EPS of -$0.98 misses by $0.20. Revenue of $13.5M (-64.6% Y/Y) misses by $3.02M. Fiscal 2022 Outlook For fiscal 2022, the Company expects net revenue to be in the range of $64 million to $66 million vs $73.94M consensus.Seeking Alpha • Aug 04Vapotherm draws downgrade at William Blair after 2Q resultsVapotherm, Inc. (NYSE:VAPO), a high-velocity therapy provider targeting patients with respiratory distress, continues to trade sharply lower after the company reported lower-than-expected 2Q 2022 results that prompted William Blair to downgrade its shares. The analysts led by Margaret Kaczor attribute the revenue miss to pressure on disposables as hospitals destocked the inventory purchased during the Omicron wave. However, the team remains optimistic about the benefit Vapotherm (VAPO) can count on due to the sizable installed base established during the COVID. In addition, they highlight the management's long-term strategy to become a patient management company for complex lung disease. However, they downgrade the stock to Market Perform from Outperform, noting the concerns over low liquidity and near-term uncertainty. Wall Street has remained bullish on Vapotherm (VAPO) stock, with an average rating of Buy from analysts, while Seeking Alpha Author ratings indicated a Hold rating. However, Seeking Alpha's quant system, which consistently beats the market, continued to rate Vapotherm (VAPO) a Strong Sell since March.Price Target Changed • Jul 06Price target decreased to US$4.83Down from US$5.50, the current price target is an average from 4 analysts. New target price is 94% above last closing price of US$2.49. Stock is down 89% over the past year. The company is forecast to post a net loss per share of US$3.11 next year compared to a net loss per share of US$2.31 last year.Seeking Alpha • May 11Vapotherm: Out Of AirVapotherm has seen a boom induced by the pandemic reverse violently. The pandemic has not boosted Vapotherm's business, as losses have only increased during this period of time. With revenues down to much lower levels and losses being very substantial, there are no (quick) fixes in sight.Major Estimate Revision • Mar 03Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from US$102.9m to US$104.5m. Forecast EPS reduced from -US$2.24 to -US$2.57 per share. Medical Equipment industry in the US expected to see average net income growth of 20% next year. Consensus price target down from US$39.00 to US$27.00. Share price rose 17% to US$14.89 over the past week.Reported Earnings • Feb 27Full year 2021 earnings: EPS and revenues exceed analyst expectationsFull year 2021 results: US$2.31 loss per share (down from US$2.16 loss in FY 2020). Revenue: US$113.3m (down 9.9% from FY 2020). Net loss: US$59.8m (loss widened 16% from FY 2020). Revenue exceeded analyst estimates by 3.2%. Earnings per share (EPS) also surpassed analyst estimates by 3.6%. Over the next year, revenue is expected to shrink by 9.6% compared to a 11% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.Price Target Changed • Feb 26Price target decreased to US$34.33Down from US$41.00, the current price target is an average from 4 analysts. New target price is 125% above last closing price of US$15.29. Stock is down 37% over the past year. The company is forecast to post a net loss per share of US$2.23 next year compared to a net loss per share of US$2.16 last year.분석 기사 • Jan 24Is Vapotherm (NYSE:VAPO) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Reported Earnings • Nov 06Third quarter 2021 earnings released: US$0.52 loss per share (vs US$0.49 loss in 3Q 2020)The company reported a solid third quarter result with improved revenues and control over costs, although losses increased. Third quarter 2021 results: Revenue: US$38.1m (up 25% from 3Q 2020). Net loss: US$13.6m (loss widened 9.0% from 3Q 2020).Executive Departure • Oct 12Chief Accounting Officer Joel Dube has left the companyOn the 6th of October, Joel Dube's tenure as Chief Accounting Officer ended. We don't have any record of a personal shareholding under Joel's name. A total of 4 executives have left over the last 12 months. The current median tenure of the management team is 6.46 years.Recent Insider Transactions Derivative • Aug 15Senior VP notifies of intention to sell stockJohn Landry intends to sell 20k shares in the next 90 days after lodging an Intent To Sell Form on the 9th of August. If the sale is conducted around the recent share price of US$27.51, it would amount to US$550k. Since September 2020, John's direct individual holding has decreased from 117.39k shares to 108.71k. Company insiders have collectively bought US$4.3m more than they sold, via options and on-market transactions, in the last 12 months.Reported Earnings • Aug 11Second quarter 2021 earnings released: US$0.67 loss per share (vs US$0.35 loss in 2Q 2020)The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: US$20.6m (down 41% from 2Q 2020). Net loss: US$17.3m (loss widened 115% from 2Q 2020).Recent Insider Transactions Derivative • Jul 31Senior VP & Chief Commercial Officer exercised options and sold US$170k worth of stockOn the 28th of July, Gregoire Ramade exercised 8k options at a strike price of around US$3.78 and sold these shares for an average price of US$25.00 per share. This trade did not impact their existing holding. Since September 2020, Gregoire has owned 10.71k shares directly. Company insiders have collectively bought US$8.4m more than they sold, via options and on-market transactions, in the last 12 months.Seeking Alpha • Jul 11Vapotherm: Hardly Breathing RoomVapotherm has benefited from the pandemic, at least sales saw a boost, but earnings did not. 2021 saw a solid start to the year, but the guidance for the remainder of the year is not inspiring, both in terms of sales and losses. Given all of this, I am not surprised to see shares under pressure, as I think it is too early to go bottom fishing here just yet.Recent Insider Transactions • Jun 30Insider recently bought US$4.8m worth of stockOn the 28th of June, Thomas Smith bought around 200k shares on-market at roughly US$23.84 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$9.6m more in shares than they have sold in the last 12 months.Executive Departure • Jun 25Independent Director Marina Hahn has left the companyOn the 22nd of June, Marina Hahn's tenure as Independent Director ended after 3.7 years in the role. As of March 2021, Marina still personally held 20.68k shares (US$497k worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 6.13 years.Recent Insider Transactions • May 19Independent Chairman of the Board recently bought US$170k worth of stockOn the 13th of May, James Liken bought around 10k shares on-market at roughly US$16.99 per share. This was the largest purchase by an insider in the last 3 months. This was James' only on-market trade for the last 12 months.분석 기사 • May 10Health Check: How Prudently Does Vapotherm (NYSE:VAPO) Use Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Reported Earnings • May 06First quarter 2021 earnings released: US$0.40 loss per share (vs US$0.66 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: US$32.3m (up 69% from 1Q 2020). Net loss: US$10.4m (loss narrowed 25% from 1Q 2020).분석 기사 • Mar 12The Independent Director of Vapotherm, Inc. (NYSE:VAPO), Anthony Arnerich, Just Bought 59% More SharesInvestors who take an interest in Vapotherm, Inc. ( NYSE:VAPO ) should definitely note that the Independent Director...Recent Insider Transactions • Mar 12Independent Director recently bought US$109k worth of stockOn the 4th of March, Anthony Arnerich bought around 5k shares on-market at roughly US$21.84 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$4.7m more in shares than they have sold in the last 12 months.분석 기사 • Mar 11Announcing: Vapotherm (NYSE:VAPO) Stock Increased An Energizing 225% In The Last YearVapotherm, Inc. ( NYSE:VAPO ) shareholders have seen the share price descend 29% over the month. Despite this, the...Reported Earnings • Feb 25Full year 2020 earnings released: US$2.16 loss per share (vs US$2.74 loss in FY 2019)The company reported a solid full year result with improved revenues and control over costs, although losses were not reduced. Full year 2020 results: Revenue: US$125.7m (up 161% from FY 2019). Net loss: US$51.5m (flat on FY 2019).Analyst Estimate Surprise Post Earnings • Feb 25Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 6.0%. Over the next year, revenue is expected to shrink by 29% compared to a 20% growth forecast for the Medical Equipment industry in the US.Is New 90 Day High Low • Feb 25New 90-day low: US$23.17The company is down 9.0% from its price of US$25.37 on 27 November 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 10.0% over the same period.Recent Insider Transactions Derivative • Jan 28Senior VP & Chief Commercial Officer notifies of intention to sell stockGregoire Ramade intends to sell roughly 8.00k shares in the next 90 days after lodging an Intent To Sell Form on the 20th of January. If the sale is conducted around the recent share price of US$31.92, it would amount to US$255k. Since March 2020, Gregoire's direct individual holding has decreased from 88.25k shares to 10.71k. Company insiders have collectively bought US$1.8m more than they sold, via options and on-market transactions, in the last 12 months.Recent Insider Transactions Derivative • Jan 23Senior VP & Chief Commercial Officer exercised options and sold US$56k worth of stockOn the 20th of January, Gregoire Ramade exercised 2.00k options at a strike price of around US$3.78 and sold these shares for an average price of US$31.92 per share. This trade did not impact their existing holding. Since March 2020, Gregoire's direct individual holding has decreased from 88.25k shares to 10.71k. Company insiders have collectively bought US$1.8m more than they sold, via options and on-market transactions, in the last 12 months.분석 기사 • Jan 19Does Vapotherm (NYSE:VAPO) Have A Healthy Balance Sheet?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is New 90 Day High Low • Jan 13New 90-day high: US$32.08The company is up 7.0% from its price of US$29.95 on 14 October 2020. The American market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 8.0% over the same period.분석 기사 • Dec 14Thomas Smith of Vapotherm, Inc. (NYSE:VAPO) Just Spent US$217k On SharesPotential Vapotherm, Inc. ( NYSE:VAPO ) shareholders may wish to note that insider Thomas Smith recently bought US$217k...Recent Insider Transactions • Dec 13Insider recently bought US$217k worth of stockOn the 9th of December, Thomas Smith bought around 8k shares on-market at roughly US$27.14 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$4.6m more in shares than they have sold in the last 12 months.분석 기사 • Dec 11Investors Who Bought Vapotherm (NYSE:VAPO) Shares A Year Ago Are Now Up 132%Unless you borrow money to invest, the potential losses are limited. But if you pick the right stock, you can make a...Major Estimate Revision • Dec 03Analysts update estimatesThe 2020 consensus revenue estimate increased from US$103.9m to US$117.0m. Earning per share (EPS) estimate remained mostly unchanged at -US$2.05. The Medical Equipment industry in the US is expected to see an average net income growth of 25% next year. The consensus price target of US$42.67 was unchanged from the last update. Share price is up 9.1% to US$26.38 over the past week.Is New 90 Day High Low • Nov 10New 90-day low: US$23.44The company is down 19% from its price of US$28.86 on 12 August 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Analyst Estimate Surprise Post Earnings • Nov 06Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 27%. Earnings per share (EPS) missed analyst estimates by 12%. Over the next year, revenue is expected to shrink by 11% compared to a 16% growth forecast for the Medical Equipment industry in the US.Reported Earnings • Nov 06Third quarter 2020 earnings released: US$0.49 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: US$30.6m (up 183% from 3Q 2019). Net loss: US$12.4m (loss narrowed 2.5% from 3Q 2019).Price Target Changed • Nov 06Price target lowered to US$42.67Down from US$47.33, the current price target is an average from 4 analysts. The new target price is 51% above the current share price of US$28.26. As of last close, the stock is up 226% over the past year.매출 및 비용 세부 내역Vapotherm가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:VAPO 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비30 Jun 2471-54451331 Mar 2470-55481431 Dec 2369-58521430 Sep 2368-69581530 Jun 2366-81651731 Mar 2363-108681931 Dec 2267-113752030 Sep 2270-110802130 Jun 2295-98892031 Mar 22103-72941931 Dec 21113-60931830 Sep 21132-58991830 Jun 21124-57921931 Mar 21139-48921931 Dec 20126-52891730 Sep 2098-47761630 Jun 2078-47671431 Mar 2055-52601331 Dec 1948-51561330 Sep 1947-51541230 Jun 1945-48511131 Mar 1944-47491031 Dec 1842-4345930 Sep 1841-3942830 Jun 1840-3739831 Mar 1838-3336831 Dec 1736-3134831 Dec 1630-23266양질의 수익: VAPO 은(는) 현재 수익성이 없습니다.이익 마진 증가: VAPO는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: VAPO은 수익성이 없으며 지난 5년 동안 손실이 연평균 10.3% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 VAPO의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: VAPO은 수익성이 없어 지난 해 수익 성장률을 Medical Equipment 업계(15.6%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: VAPO의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YHealthcare 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/09/19 13:00종가2024/09/19 00:00수익2024/06/30연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Vapotherm, Inc.는 5명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Robert HopkinsBofA Global ResearchMichael GormanBTIGWilliam PlovanicCanaccord Genuity2명의 분석가 더 보기
공고 • Nov 02Vapotherm, Inc. to Report Q3, 2023 Results on Nov 08, 2023Vapotherm, Inc. announced that they will report Q3, 2023 results After-Market on Nov 08, 2023
공고 • Jul 26Vapotherm, Inc. to Report Q2, 2023 Results on Aug 08, 2023Vapotherm, Inc. announced that they will report Q2, 2023 results After-Market on Aug 08, 2023
공고 • May 05+ 1 more updateVapotherm, Inc. Reports Impairment of Long-Lived and Intangible Assets for the First Quarter Ended March 31, 2023Vapotherm, Inc. reported impairment of long-lived and intangible assets for the first quarter ended March 31, 2023. For the quarter, the company reported impairment of long-lived and intangible assets of $432,000.
공고 • Feb 09+ 2 more updatesVapotherm, Inc. to Report Q4, 2022 Results on Feb 23, 2023Vapotherm, Inc. announced that they will report Q4, 2022 results After-Market on Feb 23, 2023
Reported Earnings • Feb 27Full year 2021 earnings: EPS and revenues exceed analyst expectationsFull year 2021 results: US$2.31 loss per share (down from US$2.16 loss in FY 2020). Revenue: US$113.3m (down 9.9% from FY 2020). Net loss: US$59.8m (loss widened 16% from FY 2020). Revenue exceeded analyst estimates by 3.2%. Earnings per share (EPS) also surpassed analyst estimates by 3.6%. Over the next year, revenue is expected to shrink by 9.6% compared to a 11% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 06Third quarter 2021 earnings released: US$0.52 loss per share (vs US$0.49 loss in 3Q 2020)The company reported a solid third quarter result with improved revenues and control over costs, although losses increased. Third quarter 2021 results: Revenue: US$38.1m (up 25% from 3Q 2020). Net loss: US$13.6m (loss widened 9.0% from 3Q 2020).
공고 • Sep 20Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC completed the acquisition of Vapotherm, Inc. (OTCPK:VAPO) from a group of shareholders.Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC executed the non binding term sheet to acquire Vapotherm, Inc. (OTCPK:VAPO) from a group of shareholders on April 29, 2024. Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC entered into definitive merger agreement to acquire Vapotherm, Inc. from a group of shareholders for $15.2 million on June 17, 2024. Vapotherm’s stockholders will receive $2.18 in cash for each outstanding share of Company common stock. Perceptive will invest $50.0 million of new preferred equity capital into the business, a portion of which will be used to fund the merger consideration and make certain closing-related payments. Upon termination of the Merger Agreement under certain specified circumstances, Vapotherm will be required to pay Perceptive a termination fee of $1.0 million. Acting upon the recommendation of the Special Committee, the Board approved the merger agreement and the transaction and has recommended that the Company’s stockholders approve the adoption of the merger agreement and approve the transaction on the terms set forth in the merger agreement. The board of directors of Perceptive also approved the agreement. The transaction is expected to close in the second half of 2024. Eric Blanchard and Amelia Runyan Davis of Cooley LLP is acting as legal counsel to Perceptive and Latham & Watkins LLP is acting as legal counsel to SLR. Scalar, LLC is acting as financial advisor and fairness opinion provider to the Special Committee and Paul Kinsella and Sarah Young of Ropes & Gray LLP is acting as legal counsel to the Vapotherm. Haim Zaltzman and Daniel Mun of Latham & Watkins LLP acted as legal counsel for SLR Investment Corp., public fund managed by SLR Capital Partners, LLC. Vapotherm has retained Morrow Sodali LLC, a proxy solicitor, to solicit proxies in connection with the Special Meeting at a cost of approximately $20,000 plus expenses. Scalar received a fee of $140,000 from Vapotherm for providing its services and rendering its opinion. Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC completed the acquisition of Vapotherm, Inc. (OTCPK:VAPO) from a group of shareholders on September 20, 2024. Effective as of the closing of the merger, trading of Vapotherm’s common stock has been suspended on OTCQX, and Vapotherm has requested that its common stock be delisted from OTCQX. Vapotherm shareholders approved the transaction on September 19, 2024.
공고 • Jun 18Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC entered into definitive merger agreement to acquire Vapotherm, Inc. (OTCPK:VAPO) for $15.1 million.Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC entered into definitive merger agreement to acquire Vapotherm, Inc. (OTCPK:VAPO) for $15.1 million on June 17, 2024. Vapotherm’s stockholders will receive $2.18 in cash for each outstanding share of Company common stock. Perceptive will invest $50.0 million of new preferred equity capital into the business, a portion of which will be used to fund the merger consideration and make certain closing-related payments. Acting upon the recommendation of the Special Committee, the Board approved the merger agreement and the transaction and has recommended that the Company’s stockholders approve the adoption of the merger agreement and approve the transaction on the terms set forth in the merger agreement. The transaction is expected to close in the second half of 2024. Cooley LLP is acting as legal counsel to Perceptive and Latham & Watkins LLP is acting as legal counsel to SLR. Scalar, LLC is acting as financial advisor to the Special Committee and Ropes & Gray LLP is acting as legal counsel to the Vapotherm.
공고 • Mar 15Vapotherm, Inc. to Unveil Access365 Home Ventilation Solution at MEDTRADEVapotherm, Inc. announced the debut of its Access365™ Home Ventilation Solution at the upcoming MEDTRADE conference. The highly anticipated Access365 home ventilator will be unveiled at MEDTRADE Dallas on March 27th. The device is designed to reduce hospital readmissions, improve patient quality of life, and reduce HME costs for late-stage hypercapnic COPD patients. In addition to VAPS and volume control/assist ventilation modes and Vapotherm's proven high velocity therapy, the ventilator incorporates a built-in medical grade humidifier and integrated Bluetooth pulse oximetry and spirometry. The Access365 Home Ventilation Solution also includes cloud connectivity to enable remote data retrieval and system upgrades and a patient engagement platform which breaks the cycle of symptom exacerbation and readmission through early identification of worsening symptoms allowing more rapid clinical intervention. This proprietary algorithm resulted in up to a 41% reduction in late-stage COPD hospital readmissions. Vapotherm anticipates receiving FDA clearance for Access365 in early 2025.
공고 • Dec 15The New York Stock Exchange to Commence Delisting Proceedings against VapothermThe New York Stock Exchange (‘NYSE’, the ‘Exchange’) announced that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Vapotherm, Inc. (the ‘Company’) from the NYSE. Trading in the Company’s common stock will be suspended immediately. NYSE Regulation reached its decision to delist the Company’s common stock pursuant to Section 802.01B of the NYSE’s Listed Company Manual because the Company had fallen below the NYSE’s continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15,000,000. The Company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange. The NYSE will apply to the Securities and Exchange Commission to delist the common stock upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision.
공고 • Nov 11Vapotherm, Inc. Revises Revenue Guidance for the Full Year 2023Vapotherm, Inc. revised revenue guidance for the full Year 2023. The Company now expects full year revenue to be between $69 million and $71 million, a decrease from the Company’s previous fiscal outlook of $70 million to $73 million.
공고 • Nov 02Vapotherm, Inc. to Report Q3, 2023 Results on Nov 08, 2023Vapotherm, Inc. announced that they will report Q3, 2023 results After-Market on Nov 08, 2023
공고 • Sep 26Vapotherm Announces Presentation of an Investigator-Initiated Clinical Trial, 'High Flow Humidified Oxygen as an Early Intervention in Children with Acute Severe Asthma - a Feasibility Randomized Controlled Trial' at the European Respiratory Society International Congress 2023Vapotherm, Inc. announced the presentation of an Investigator-initiated clinical trial, “High flow humidified oxygen as an early intervention in children with acute severe asthma - a feasibility randomized controlled trial” at the European Respiratory Society International Congress 2023. The study was conducted through the Brighton and Sussex Clinical Trial Unit at University Hospitals, Sussex, England under the direction of Drs. Hector Rojas-Anaya and Paul Seddon. Children who presented to the Emergency Department with acute, severe, asthma exacerbations that did not respond to initial pharmacologic treatment were randomized to either HVNI or standard nasal oxygen therapy. 86% (19/22) of children treated with standard oxygen required escalation of therapy, while only 61% (17/28) of children treated with HVNI needed further escalation. In addition, children treated with HVNI met hospital discharge criteria in a median time of 29 hours, compared to a median time of 37 hours for those treated with standard oxygen. Studies of acute asthma and other emergent conditions are limited, in part, by the challenge of obtaining informed consent. This study demonstrated the feasibility of pediatric emergency studies utilizing coordinated care and delayed informed consent.
공고 • Aug 09Vapotherm, Inc. Revises Earnings Guidance for Fiscal 2023Vapotherm, Inc. revised earnings guidance For fiscal 2023. For the period, the Company now expects full year revenue to be between $70 million and $73 million, a decrease from its previous expectation of $77 million to $79 million. The Company now expects full year gross margins of 43% to 45%, a decrease from its previous expectation of 48% to 50%.
공고 • Jul 26Vapotherm, Inc. to Report Q2, 2023 Results on Aug 08, 2023Vapotherm, Inc. announced that they will report Q2, 2023 results After-Market on Aug 08, 2023
공고 • May 05+ 1 more updateVapotherm, Inc. Reports Impairment of Long-Lived and Intangible Assets for the First Quarter Ended March 31, 2023Vapotherm, Inc. reported impairment of long-lived and intangible assets for the first quarter ended March 31, 2023. For the quarter, the company reported impairment of long-lived and intangible assets of $432,000.
공고 • Feb 10Vapotherm Receives Price Cure Notification Letter from the NYSE Indicates its Stock Price Above the NYSE's Minimum RequirementVapotherm, Inc. announced that with respect to the previously reported two delisting notices from the New York Stock Exchange (NYSE) in 2022, the company reported that it recently received a price cure notification letter from the NYSE indicating the company’s stock price was above the NYSE’s minimum requirement of one dollar per share based on a 30-trading day average. Accordingly, the company is no longer considered below the one dollar continued listing criterion. The company recently received a plan acceptance letter from the NYSE indicating it had accepted the company’s previously submitted business plan to cure its non-compliance with its market capitalization requirement. As set forth in the acceptance letter, the NYSE will continue listing the Company and will perform quarterly reviews for an 18-month period that started September 27, 2022 (the date the delisting notice was received by the Company) for compliance with the goals and initiatives outlined in the Company’s business plan, which are consistent with the key initiatives the Company has publicly disclosed. The Company will need to achieve the minimum continued listing standards of either average global market capitalization over a consecutive 30 trading-day period of $50 million or total stockholders’ equity of $50 million at the completion of the 18-month period.
공고 • Feb 09+ 2 more updatesVapotherm, Inc. to Report Q4, 2022 Results on Feb 23, 2023Vapotherm, Inc. announced that they will report Q4, 2022 results After-Market on Feb 23, 2023
Seeking Alpha • Feb 08Vapotherm announces $23M private placementGlobal medical technology company, Vapotherm (NYSE:VAPO) has entered into a securities purchase agreement with investors through a private placement financing for gross proceeds of ~$23M. Pursuant to the agreement, the company agreed to issue 17.5M shares and pre-funded warrants to purchase up to 4.4M shares. The pre-funded warrants will have a term of 30 years and an exercise price of $0.001 per share. Closing expected to occur on February 10, 2023. Net proceeds from the offering primarily for sales and marketing, working capital, and other general corporate purposes. Stock trades 8% higher.
Seeking Alpha • Nov 02Vapotherm GAAP EPS of -$0.98 misses by $0.20, revenue of $13.5M misses by $3.02MVapotherm press release (NYSE:VAPO): Q3 GAAP EPS of -$0.98 misses by $0.20. Revenue of $13.5M (-64.6% Y/Y) misses by $3.02M. Fiscal 2022 Outlook For fiscal 2022, the Company expects net revenue to be in the range of $64 million to $66 million vs $73.94M consensus.
Seeking Alpha • Aug 04Vapotherm draws downgrade at William Blair after 2Q resultsVapotherm, Inc. (NYSE:VAPO), a high-velocity therapy provider targeting patients with respiratory distress, continues to trade sharply lower after the company reported lower-than-expected 2Q 2022 results that prompted William Blair to downgrade its shares. The analysts led by Margaret Kaczor attribute the revenue miss to pressure on disposables as hospitals destocked the inventory purchased during the Omicron wave. However, the team remains optimistic about the benefit Vapotherm (VAPO) can count on due to the sizable installed base established during the COVID. In addition, they highlight the management's long-term strategy to become a patient management company for complex lung disease. However, they downgrade the stock to Market Perform from Outperform, noting the concerns over low liquidity and near-term uncertainty. Wall Street has remained bullish on Vapotherm (VAPO) stock, with an average rating of Buy from analysts, while Seeking Alpha Author ratings indicated a Hold rating. However, Seeking Alpha's quant system, which consistently beats the market, continued to rate Vapotherm (VAPO) a Strong Sell since March.
Price Target Changed • Jul 06Price target decreased to US$4.83Down from US$5.50, the current price target is an average from 4 analysts. New target price is 94% above last closing price of US$2.49. Stock is down 89% over the past year. The company is forecast to post a net loss per share of US$3.11 next year compared to a net loss per share of US$2.31 last year.
Seeking Alpha • May 11Vapotherm: Out Of AirVapotherm has seen a boom induced by the pandemic reverse violently. The pandemic has not boosted Vapotherm's business, as losses have only increased during this period of time. With revenues down to much lower levels and losses being very substantial, there are no (quick) fixes in sight.
Major Estimate Revision • Mar 03Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from US$102.9m to US$104.5m. Forecast EPS reduced from -US$2.24 to -US$2.57 per share. Medical Equipment industry in the US expected to see average net income growth of 20% next year. Consensus price target down from US$39.00 to US$27.00. Share price rose 17% to US$14.89 over the past week.
Reported Earnings • Feb 27Full year 2021 earnings: EPS and revenues exceed analyst expectationsFull year 2021 results: US$2.31 loss per share (down from US$2.16 loss in FY 2020). Revenue: US$113.3m (down 9.9% from FY 2020). Net loss: US$59.8m (loss widened 16% from FY 2020). Revenue exceeded analyst estimates by 3.2%. Earnings per share (EPS) also surpassed analyst estimates by 3.6%. Over the next year, revenue is expected to shrink by 9.6% compared to a 11% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
Price Target Changed • Feb 26Price target decreased to US$34.33Down from US$41.00, the current price target is an average from 4 analysts. New target price is 125% above last closing price of US$15.29. Stock is down 37% over the past year. The company is forecast to post a net loss per share of US$2.23 next year compared to a net loss per share of US$2.16 last year.
분석 기사 • Jan 24Is Vapotherm (NYSE:VAPO) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Reported Earnings • Nov 06Third quarter 2021 earnings released: US$0.52 loss per share (vs US$0.49 loss in 3Q 2020)The company reported a solid third quarter result with improved revenues and control over costs, although losses increased. Third quarter 2021 results: Revenue: US$38.1m (up 25% from 3Q 2020). Net loss: US$13.6m (loss widened 9.0% from 3Q 2020).
Executive Departure • Oct 12Chief Accounting Officer Joel Dube has left the companyOn the 6th of October, Joel Dube's tenure as Chief Accounting Officer ended. We don't have any record of a personal shareholding under Joel's name. A total of 4 executives have left over the last 12 months. The current median tenure of the management team is 6.46 years.
Recent Insider Transactions Derivative • Aug 15Senior VP notifies of intention to sell stockJohn Landry intends to sell 20k shares in the next 90 days after lodging an Intent To Sell Form on the 9th of August. If the sale is conducted around the recent share price of US$27.51, it would amount to US$550k. Since September 2020, John's direct individual holding has decreased from 117.39k shares to 108.71k. Company insiders have collectively bought US$4.3m more than they sold, via options and on-market transactions, in the last 12 months.
Reported Earnings • Aug 11Second quarter 2021 earnings released: US$0.67 loss per share (vs US$0.35 loss in 2Q 2020)The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: US$20.6m (down 41% from 2Q 2020). Net loss: US$17.3m (loss widened 115% from 2Q 2020).
Recent Insider Transactions Derivative • Jul 31Senior VP & Chief Commercial Officer exercised options and sold US$170k worth of stockOn the 28th of July, Gregoire Ramade exercised 8k options at a strike price of around US$3.78 and sold these shares for an average price of US$25.00 per share. This trade did not impact their existing holding. Since September 2020, Gregoire has owned 10.71k shares directly. Company insiders have collectively bought US$8.4m more than they sold, via options and on-market transactions, in the last 12 months.
Seeking Alpha • Jul 11Vapotherm: Hardly Breathing RoomVapotherm has benefited from the pandemic, at least sales saw a boost, but earnings did not. 2021 saw a solid start to the year, but the guidance for the remainder of the year is not inspiring, both in terms of sales and losses. Given all of this, I am not surprised to see shares under pressure, as I think it is too early to go bottom fishing here just yet.
Recent Insider Transactions • Jun 30Insider recently bought US$4.8m worth of stockOn the 28th of June, Thomas Smith bought around 200k shares on-market at roughly US$23.84 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$9.6m more in shares than they have sold in the last 12 months.
Executive Departure • Jun 25Independent Director Marina Hahn has left the companyOn the 22nd of June, Marina Hahn's tenure as Independent Director ended after 3.7 years in the role. As of March 2021, Marina still personally held 20.68k shares (US$497k worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 6.13 years.
Recent Insider Transactions • May 19Independent Chairman of the Board recently bought US$170k worth of stockOn the 13th of May, James Liken bought around 10k shares on-market at roughly US$16.99 per share. This was the largest purchase by an insider in the last 3 months. This was James' only on-market trade for the last 12 months.
분석 기사 • May 10Health Check: How Prudently Does Vapotherm (NYSE:VAPO) Use Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Reported Earnings • May 06First quarter 2021 earnings released: US$0.40 loss per share (vs US$0.66 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: US$32.3m (up 69% from 1Q 2020). Net loss: US$10.4m (loss narrowed 25% from 1Q 2020).
분석 기사 • Mar 12The Independent Director of Vapotherm, Inc. (NYSE:VAPO), Anthony Arnerich, Just Bought 59% More SharesInvestors who take an interest in Vapotherm, Inc. ( NYSE:VAPO ) should definitely note that the Independent Director...
Recent Insider Transactions • Mar 12Independent Director recently bought US$109k worth of stockOn the 4th of March, Anthony Arnerich bought around 5k shares on-market at roughly US$21.84 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$4.7m more in shares than they have sold in the last 12 months.
분석 기사 • Mar 11Announcing: Vapotherm (NYSE:VAPO) Stock Increased An Energizing 225% In The Last YearVapotherm, Inc. ( NYSE:VAPO ) shareholders have seen the share price descend 29% over the month. Despite this, the...
Reported Earnings • Feb 25Full year 2020 earnings released: US$2.16 loss per share (vs US$2.74 loss in FY 2019)The company reported a solid full year result with improved revenues and control over costs, although losses were not reduced. Full year 2020 results: Revenue: US$125.7m (up 161% from FY 2019). Net loss: US$51.5m (flat on FY 2019).
Analyst Estimate Surprise Post Earnings • Feb 25Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 6.0%. Over the next year, revenue is expected to shrink by 29% compared to a 20% growth forecast for the Medical Equipment industry in the US.
Is New 90 Day High Low • Feb 25New 90-day low: US$23.17The company is down 9.0% from its price of US$25.37 on 27 November 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 10.0% over the same period.
Recent Insider Transactions Derivative • Jan 28Senior VP & Chief Commercial Officer notifies of intention to sell stockGregoire Ramade intends to sell roughly 8.00k shares in the next 90 days after lodging an Intent To Sell Form on the 20th of January. If the sale is conducted around the recent share price of US$31.92, it would amount to US$255k. Since March 2020, Gregoire's direct individual holding has decreased from 88.25k shares to 10.71k. Company insiders have collectively bought US$1.8m more than they sold, via options and on-market transactions, in the last 12 months.
Recent Insider Transactions Derivative • Jan 23Senior VP & Chief Commercial Officer exercised options and sold US$56k worth of stockOn the 20th of January, Gregoire Ramade exercised 2.00k options at a strike price of around US$3.78 and sold these shares for an average price of US$31.92 per share. This trade did not impact their existing holding. Since March 2020, Gregoire's direct individual holding has decreased from 88.25k shares to 10.71k. Company insiders have collectively bought US$1.8m more than they sold, via options and on-market transactions, in the last 12 months.
분석 기사 • Jan 19Does Vapotherm (NYSE:VAPO) Have A Healthy Balance Sheet?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Is New 90 Day High Low • Jan 13New 90-day high: US$32.08The company is up 7.0% from its price of US$29.95 on 14 October 2020. The American market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 8.0% over the same period.
분석 기사 • Dec 14Thomas Smith of Vapotherm, Inc. (NYSE:VAPO) Just Spent US$217k On SharesPotential Vapotherm, Inc. ( NYSE:VAPO ) shareholders may wish to note that insider Thomas Smith recently bought US$217k...
Recent Insider Transactions • Dec 13Insider recently bought US$217k worth of stockOn the 9th of December, Thomas Smith bought around 8k shares on-market at roughly US$27.14 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$4.6m more in shares than they have sold in the last 12 months.
분석 기사 • Dec 11Investors Who Bought Vapotherm (NYSE:VAPO) Shares A Year Ago Are Now Up 132%Unless you borrow money to invest, the potential losses are limited. But if you pick the right stock, you can make a...
Major Estimate Revision • Dec 03Analysts update estimatesThe 2020 consensus revenue estimate increased from US$103.9m to US$117.0m. Earning per share (EPS) estimate remained mostly unchanged at -US$2.05. The Medical Equipment industry in the US is expected to see an average net income growth of 25% next year. The consensus price target of US$42.67 was unchanged from the last update. Share price is up 9.1% to US$26.38 over the past week.
Is New 90 Day High Low • Nov 10New 90-day low: US$23.44The company is down 19% from its price of US$28.86 on 12 August 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Analyst Estimate Surprise Post Earnings • Nov 06Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 27%. Earnings per share (EPS) missed analyst estimates by 12%. Over the next year, revenue is expected to shrink by 11% compared to a 16% growth forecast for the Medical Equipment industry in the US.
Reported Earnings • Nov 06Third quarter 2020 earnings released: US$0.49 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: US$30.6m (up 183% from 3Q 2019). Net loss: US$12.4m (loss narrowed 2.5% from 3Q 2019).
Price Target Changed • Nov 06Price target lowered to US$42.67Down from US$47.33, the current price target is an average from 4 analysts. The new target price is 51% above the current share price of US$28.26. As of last close, the stock is up 226% over the past year.